275 related articles for article (PubMed ID: 31914819)
1. Anti-IL-4/IL-13 for the treatment of asthma: the story so far.
Moran A; Pavord ID
Expert Opin Biol Ther; 2020 Mar; 20(3):283-294. PubMed ID: 31914819
[No Abstract] [Full Text] [Related]
2. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
3. IL-13 antagonists in the treatment of atopic dermatitis.
Tubau C; Puig L
Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab: A Review in Moderate to Severe Asthma.
Deeks ED
Drugs; 2019 Nov; 79(17):1885-1895. PubMed ID: 31728838
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
7. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
Parulekar AD; Kao CC; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
[TBL] [Abstract][Full Text] [Related]
8. Targeted anti-IL-13 therapies in asthma: current data and future perspectives.
Ntontsi P; Papathanassiou E; Loukides S; Bakakos P; Hillas G
Expert Opin Investig Drugs; 2018 Feb; 27(2):179-186. PubMed ID: 29334288
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab for the treatment of asthma.
Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of mepolizumab for the treatment of severe asthma.
Morjaria JB; Emma R; Fuochi V; Polosa R; Caruso M
Expert Opin Biol Ther; 2019 Jun; 19(6):491-500. PubMed ID: 31009582
[No Abstract] [Full Text] [Related]
12. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
13. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
14. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab: First Global Approval.
Shirley M
Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
[TBL] [Abstract][Full Text] [Related]
16. [Dupilumab : a new treatment for severe T2 high asthma].
Louis R; Sabbe M; Bougard N; Frix AN; Schleich F
Rev Med Liege; 2024 Apr; 79(4):255-259. PubMed ID: 38602214
[TBL] [Abstract][Full Text] [Related]
17. A review of dupilumab in the treatment of atopic diseases.
Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; MartÃnez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF; Nair P; Brusselle G; Maspero JF; Castro M; Sher L; Zhu H; Hamilton JD; Swanson BN; Khan A; Chao J; Staudinger H; Pirozzi G; Antoni C; Amin N; Ruddy M; Akinlade B; Graham NMH; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2475-2485. PubMed ID: 29782224
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]